Annual fundraiser supports the foundation's efforts to raise awareness and improve quality of life for adults and children ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, ...

Stress isnt the cause of IBD but minimising it may be your secret weapon for living better with the condition Read ahead to ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

When Phyllis Burk was diagnosed with Crohn’s disease nearly 50 years ago, it wasn’t as simple as looking up information ...

In a randomized trial, 1 day of octreotide infusion combined with endoscopic therapy proved noninferior to 5 days for acute ...

People with inflammatory bowel disease, like ulcerative colitis, are 2 to 3 times more likely to develop blood clots than ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...

AbbVie has received the U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) that ...

SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, ...